Raymond James & Associates Corcept Therapeutics Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Raymond James & Associates holds 46,590 shares of CORT stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,590

Previous 31,950 45.82%

Holding current value

$2.33 Million

Previous $1.04 Million 107.61%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$29.51 - $46.26 $432,026 - $677,246	14,640 Added 45.82%	46,590 $2.16 Million
Q2 2024 Jul 19, 2024	BUY	$22.21 - $34.48 $97,746 - $151,746	4,401 Added 15.98%	31,950 $1.04 Million
Q1 2024 Apr 22, 2024	BUY	$21.1 - $27.46 $581,283 - $756,495	27,549 New	27,549 $693,000
Q3 2022 Oct 25, 2022	BUY	$24.7 - $29.12 $23,489 - $27,693	951 Added 2.95%	33,149 $850,000
Q2 2022 Aug 12, 2022	BUY	$17.33 - $25.3 $557,991 - $814,609	32,198 New	32,198 $766,000
Q1 2021 May 14, 2021	SELL	$23.49 - $30.56 $1.65 Million - $2.15 Million	-70,264 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$16.78 - $27.3 $149,375 - $243,024	-8,902 Reduced 11.24%	70,264 $1.84 Million
Q3 2020 Nov 04, 2020	SELL	$12.46 - $19.98 $107,965 - $173,126	-8,665 Reduced 9.87%	79,166 $1.38 Million
Q2 2020 Jul 28, 2020	SELL	$11.0 - $18.26 $260,711 - $432,780	-23,701 Reduced 21.25%	87,831 $1.48 Million
Q1 2020 Apr 21, 2020	SELL	$10.11 - $14.04 $870,794 - $1.21 Million	-86,132 Reduced 43.57%	111,532 $1.33 Million
Q4 2019 Feb 12, 2020	BUY	$12.06 - $16.96 $347,412 - $488,566	28,807 Added 17.06%	197,664 $2.39 Million
Q3 2019 Nov 07, 2019	SELL	$10.41 - $14.66 $56,234 - $79,193	-5,402 Reduced 3.1%	168,857 $2.39 Million
Q2 2019 Aug 06, 2019	BUY	$9.78 - $12.76 $474,114 - $618,579	48,478 Added 38.54%	174,259 $1.94 Million
Q1 2019 May 06, 2019	SELL	$10.03 - $15.71 $569,092 - $891,369	-56,739 Reduced 31.09%	125,781 $1.48 Million
Q4 2018 Feb 11, 2019	BUY	$11.29 - $17.19 $1.28 Million - $1.95 Million	113,543 Added 164.61%	182,520 $2.44 Million
Q3 2018 Nov 14, 2018	BUY	$12.27 - $15.65 $236,896 - $302,154	19,307 Added 38.87%	68,977 $967,000
Q2 2018 Aug 14, 2018	BUY	$15.3 - $19.69 $127,020 - $163,466	8,302 Added 20.07%	49,670 $781,000
Q1 2018 May 14, 2018	BUY	$14.59 - $25.5 $21,957 - $38,377	1,505 Added 3.78%	41,368 $681,000
Q4 2017 Feb 14, 2018	SELL	$15.77 - $20.72 $865,536 - $1.14 Million	-54,885 Reduced 57.93%	39,863 $720,000
Q3 2017 Nov 13, 2017	BUY	$12.3 - $19.3 $82,656 - $129,696	6,720 Added 7.63%	94,748 $1.83 Million
Q2 2017 Aug 14, 2017	BUY	N/A	88,028	88,028 $1.04 Million

Others Institutions Holding CORT

# of Institutions

346

Shares Held

86.1M

Call Options Held

1.12M

Put Options Held

667K

View Full List

About CORCEPT THERAPEUTICS INC

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.35B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

More about CORT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Corcept Therapeutics Inc Transaction History